In SERENE-CD, TREM-1 gene expression was analysed in 106 patients who were receiving the standard dose at Week 12, and in 50 and 48 patients for endoscopic and clinical outcomes, respectively, at Week 56 [clinical data were not available at Week 56 for two patients]. The gene discussed is TREM1; the disease is Cowden disease.